On August 4, 2025, President Donald J. Trump sent letters to 17 leading pharmaceutical companies, urging them to lower prescription drug prices in the United States. He emphasized that Americans should not pay higher prices for medications than consumers in other developed nations for the same drugs. Trump warned that if the companies do not take action, the administration will utilize all available tools to address high drug pricing practices that affect American families.

Recent reports indicate that Trump’s pressure is having an impact, with companies like AstraZeneca announcing proposed price cuts for certain medications. Additionally, British drugmaker GSK has entered discussions with the Trump administration regarding strategies to reduce drug costs in the U.S. This suggests a growing acknowledgment among pharmaceutical companies of the need to respond to the administration’s demands.

Coverage of Trump’s initiative has been widespread, with various media outlets reporting on his 60-day deadline for drugmakers to implement price reductions. The responses from companies and the administration highlight ongoing discussions about drug pricing in the U.S. and the actions being taken to align American prices with those found in other countries.

Original: article